Butterfly Network vs Dozee

Butterfly Network has a disclosed valuation of $1.5B, while Dozee's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

Butterfly Network has raised more in total funding at $700M, compared to Dozee's $20M — a gap of $680M.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Dozee's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 25-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. Dozee was founded by Mudit Dandwate in 2015. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Dozee: Dozee builds a contactless remote patient monitoring system that uses a ballistocardiography sensor placed under a mattress to continuously track heart rate, respiratory rate, blood pressure trends, and sleep quality, transmitting data to an AI analysis platform that generates clinical-grade early warning scores for hospital staff. The system requires no wearables or patient cooperation, enabling continuous monitoring for elderly patients, post-surgical recovery, and ICU step-down units.\n\nThe company raised approximately $20M in Series B funding and has deployed its monitoring systems across hospitals in India and internationally, with evidence of measurable reductions in deterioration events and ICU transfers through early warning. Dozee's central monitoring dashboard allows nursing staff to oversee multiple patients simultaneously with automated deterioration alerts.\n\nContinuous patient monitoring outside of ICU settings is an underserved clinical problem globally, and particularly acute in India where nurse-to-patient ratios in general wards are often insufficient for manual vital sign monitoring. Dozee's contactless approach and AI early warning capability address both the clinical quality and resource efficiency dimensions of this challenge.

Butterfly Network was founded first in 2011, giving it 4 years of additional market experience. Dozee was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while Dozee has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and Dozee are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.